Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.51 |
| ▸ | FNTB | P49356 | 8/20 | 0.51 |
| ▸ | HTR1A | P08908 | 9/20 | 0.41 |
| ▸ | HTR7 | P34969 | 9/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241421 | 0.88 | FNTA (0.39) | FNTAFNTBHDAC8AKT1 | |
| SCHEMBL3500442 | 0.87 | FNTA (0.40) | FNTAFNTBHTR1AHTR7 | |
| SCHEMBL7246580 | 0.86 | FNTA (0.68) | FNTAFNTB | |
| SCHEMBL648863 | 0.84 | FNTA (0.52) | FNTAFNTBHTR1AHTR7HDAC8 | |
| SCHEMBL649631 | 0.84 | FNTA (0.52) | FNTAFNTBHTR1AHTR7HDAC8 | |
| SCHEMBL648862 | 0.84 | FNTA (0.52) | FNTAFNTBHTR1AHTR7HDAC8 | |
| SCHEMBL7248085 | 0.83 | BCHE (0.39) | FNTAFNTBAKT1 | |
| SCHEMBL7246722 | 0.77 | FNTA (0.33) | FNTAFNTB | |
| SCHEMBL3501244 | 0.77 | DRD4 (0.46) | FNTAFNTB | |
| SCHEMBL3502958 | 0.76 | FNTA (0.53) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602883-B1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | claimed |
| US-6387926-B1 | ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-14 | — | — | US | claimed |
| EP-0994856-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | claimed |
| EP-0994856-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999001434-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| WO-2005089515-A9 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-6602883-B1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-6387926-B1 | ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885HTR1A 3777/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885HTR1A 4871/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885HTR1A 3777/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885HTR1A 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.